The role of the LDL receptor in apolipoprotein B secretion.
about
Lysophosphatidylcholine acyltransferase 3 knockdown-mediated liver lysophosphatidylcholine accumulation promotes very low density lipoprotein production by enhancing microsomal triglyceride transfer protein expressionNormal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemiaTunicamycin induces ubiquitination and degradation of apolipoprotein B in HepG2 cellsA targeted apolipoprotein B-38.9-producing mutation causes fatty livers in mice due to the reduced ability of apolipoprotein B-38.9 to transport triglyceridesDietary Lipid Levels Influence Lipid Deposition in the Liver of Large Yellow Croaker (Larimichthys crocea) by Regulating Lipoprotein Receptors, Fatty Acid Uptake and Triacylglycerol Synthesis and Catabolism at the Transcriptional LevelExpression and localization of PCSK9 in rat hepatic cellsABCA1-dependent lipid efflux to apolipoprotein A-I mediates HDL particle formation and decreases VLDL secretion from murine hepatocytesEpigallocatechin gallate increases the formation of cytosolic lipid droplets and decreases the secretion of apoB-100 VLDLWild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cellsDecreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9Microsomal triacylglycerol transfer protein is required for lumenal accretion of triacylglycerol not associated with ApoB, as well as for ApoB lipidationHepatic secretion of apoB-100 is impaired in hypobetalipoproteinemic mice with an apoB-38.9-specifying alleleImpaired lipid levels and inflammatory response in rats exposed to cadmiumAtherogenesis and metabolic dysregulation in LDL receptor-knockout rats.Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor.PCSK9 and Atherosclerosis - Lipids and Beyond.Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acidsTargeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-IThe elevation of plasma concentrations of apoB-48-containing lipoproteins in familial hypercholesterolemia is independent of PCSK9 levels.Recent progress in understanding protein and lipid factors affecting hepatic VLDL assembly and secretion.Endoplasmic reticulum localization of the low density lipoprotein receptor mediates presecretory degradation of apolipoprotein BAbnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis.Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins.Apolipoprotein B metabolism: tracer kinetics, models, and metabolic studies.Apolipoprotein E4 exaggerates diabetic dyslipidemia and atherosclerosis in mice lacking the LDL receptor.Disruption of LDL but not VLDL clearance in autosomal recessive hypercholesterolemiaPolyphenols and human health: prevention of disease and mechanisms of action.Hepatic ABCA1 and VLDL triglyceride production.Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments.Impact of 3'UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot studyHigh density lipoprotein metabolism in low density lipoprotein receptor-deficient mice.Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism.Thematic review series: patient-oriented research. What we have learned about VLDL and LDL metabolism from human kinetics studies.Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease.Diabetic atherosclerosis in APOE*4 mice: synergy between lipoprotein metabolism and vascular inflammationInhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.Hepatic insulin signaling regulates VLDL secretion and atherogenesis in mice.Saturated fatty acids activate ERK signaling to downregulate hepatic sortilin 1 in obese and diabetic mice.
P2860
Q24314933-EA4DF0EC-C6FE-4920-945B-F75D5FB3DB64Q28204028-76D36663-8F04-4822-A5ED-5D85F9986CF9Q28347626-F0174E85-DE99-4D90-AAC9-1C9DD63B06C9Q28507306-8F073956-6340-4AF9-973D-853E6B3F3705Q28545855-0F652D7D-A05B-4DF3-8410-1BEC30E88266Q28568944-10F308EB-660D-47BB-9679-A8BF03911A6AQ28569109-A35CF021-D24D-4467-9F54-87EBCFDFA48AQ28582707-87E5DA63-29D3-4FF4-AB0D-470CBC2C70D7Q28585300-60DC5BAC-8547-43D6-B102-3F971D0FBF0CQ28588292-EE6146DC-44B4-48E9-BDF0-16370A13123DQ28590076-C3236BE7-A997-4E8F-9B8A-FD8E4A591397Q28593031-B24A6E59-A72F-4880-A14B-AA2C802D3F0AQ28596181-4A45AEB0-2579-43C5-A8BC-BCAF5CB021CAQ30968588-AB7F6FB9-22CA-41DE-8BD4-F069A633D258Q33182404-ED065912-126D-4A92-B74F-6B93D4E2D76FQ33675963-47CE1051-1C2C-4EDF-83B9-25D846206D7AQ33688639-CC9E51B3-B190-4E89-B873-C4E1D8C85032Q33736540-2904E1E8-AB52-4DF3-8282-FA6574080A69Q33804948-2ADBC25B-4BAA-48E3-BAA5-FFD6D722A81EQ33863614-3A3DD8A6-C477-449D-8B78-05B5C2A5C00AQ34047812-07232E3C-90DA-4E3F-A835-552A5972D396Q34176669-686C7771-B9C4-4F7C-8F97-04E154A16C62Q34321484-A23BE6FD-DFAA-4F7F-9474-0447A89A2CB9Q34433146-323E9A32-A290-40B2-B056-95848B8C662EQ34634838-F1BB6C9E-7BA4-4E8B-95FB-FBBAAAC837A9Q34640735-E5F00D49-5B30-43DA-A226-EC678DF256A3Q35179999-E0651263-FCF5-45DE-BBBE-206546859DC1Q35250984-256705A8-B0CB-45DF-885D-39A983AD292BQ35670850-795D4C92-42AB-47BF-B845-6373B6FB195BQ35737630-0B05114D-D4B1-408A-B58C-574B699C91D1Q35747264-B8FBB72B-8060-43BB-8751-6F9B37A9CD28Q35791503-85F1573C-AB91-4B38-A15B-A950674CEB30Q36197688-E864E114-DA06-48E4-BFF9-54C8540E0C3CQ36359516-B0A046A3-A2D4-4186-928F-B2907E85EA90Q36487064-91973D98-AB3D-436B-B63E-ABE6FC28DB57Q36536256-AB4F2407-9B06-411B-B66B-682331AAA534Q36658372-F5B696DB-4A8B-4820-9329-DDA93373210DQ36870580-1274D73C-9834-490A-9D29-83A05CE794F8Q37143361-F3912E2A-AABD-4987-AD77-7152D44AFB6FQ37163044-68DD489A-BA2A-477B-97A0-F007E66B3381
P2860
The role of the LDL receptor in apolipoprotein B secretion.
description
2000 nî lūn-bûn
@nan
2000 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The role of the LDL receptor in apolipoprotein B secretion.
@ast
The role of the LDL receptor in apolipoprotein B secretion.
@en
type
label
The role of the LDL receptor in apolipoprotein B secretion.
@ast
The role of the LDL receptor in apolipoprotein B secretion.
@en
prefLabel
The role of the LDL receptor in apolipoprotein B secretion.
@ast
The role of the LDL receptor in apolipoprotein B secretion.
@en
P2093
P2860
P356
P1476
The role of the LDL receptor in apolipoprotein B secretion.
@en
P2093
P2860
P304
P356
10.1172/JCI8623
P407
P577
2000-02-01T00:00:00Z